Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1225

Sort by

Sort Order Select

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Matthew Lunning, Julie Vose, Loretta Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Susan O’Brien

Blood (2019) 134 (21): 1811–1820.

https://doi.org/10.1182/blood.2019002118

Published: 2019

Includes: Supplemental data

Journal Articles

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, MD, Paul Frankel, PhD, Christopher Ruel, Mehrdad Abedi, MD, Emily Schwab, BS, Caitlin L. Costello, MD, Jasmine Zain, MD, Lihua E Budde, MD PhD, Basem M. William, MRCP,MD, Francine M. Foss, MD, Brian A Jonas, MD PhD, Aaron Seth Rosenberg, MD, Edward Newman, PhD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 760.

https://doi.org/10.1182/blood-2019-124254

Published: 2019

Journal Articles

KLF4 Is Needed for Optimal Hydroxyurea Induction of Gamma-Globin in K562 Cells

Alireza Paikari, MD, Ankush Goyal, MA, Celeste K. Kanne, BA, Vivien A. Sheehan, MD PhD

Blood (2019) 134 (Supplement_1): 971.

https://doi.org/10.1182/blood-2019-131214

Published: 2019

Journal Articles

Pharmacokinetics-Guided Dosing of Hydroxyurea Can Achieve Near-Pancellular Fetal Hemoglobin Expression in Sickle Cell Anemia: F-Cell Analysis As a Benchmark for Disease-Modifying Therapy

Charles T. Quinn, MD, Omar Niss, MD, Amanda Pfeiffer, Jennifer Korpik, Holly Bonar, Mary Reynaud, Russell E. Ware, MD PhD, Patrick T. McGann, MD

Blood (2019) 134 (Supplement_1): 892.

https://doi.org/10.1182/blood-2019-130414

Published: 2019

Journal Articles

Splenomegaly in Children with Sickle Cell Anemia Receiving Hydroxyurea in Sub-Saharan Africa

Leon Tshilolo, MD PhD, George A. Tomlinson, PhD BSc, MSc, Patrick T. McGann, MD, Teresa S. Latham, MA, Peter Olupot-Olupot, Brigida Santos, Banu Aygun, MD, Susan Stuber, MA, Adam Lane, PhD, Thomas N. Williams, Russell E. Ware, MD PhD

Blood (2019) 134 (Supplement_1): 993.

https://doi.org/10.1182/blood-2019-129937

Published: 2019

Journal Articles

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Motoo Nagane, MD PhD, Yoshitaka Narita, MD PhD, Kazuhiko Mishima, MD PhD, Yasuhito Terui, MD PhD, Yoshiki Arakawa, MD PhD, Hajime Yonezawa, MD PhD, Katsunori Asai, MD PhD, Noriko Fukuhara, MD PhD, Kazuhiko Sugiyama, MD PhD, Naoki Shinojima, MD PhD, Junsaku Kitagawa, Arata Aoi, Ryo Nishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 1586.

https://doi.org/10.1182/blood-2019-123362

Published: 2019

Journal Articles

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Sigrid Dubois, PhD, Jennifer Hsu, RN, Jeffrey Schlom, PhD, James Gulley, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 1558.

https://doi.org/10.1182/blood-2019-128945

Published: 2019

Journal Articles

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

Neha Mehta-Shah, MD, Peter A. Riedell, MD, Nancy L. Bartlett, MD, Amanda F Cashen, MD, Brad S. Kahl, MD, Todd A Fehniger, MD PhD, Chaz Moreno, Jingxia Liu, MS, PhD, Kenneth R. Carson, MD PhD

Blood (2019) 134 (Supplement_1): 1550.

https://doi.org/10.1182/blood-2019-124185

Published: 2019

Journal Articles

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Sarit Assouline, MD, Amitkumar Mehta, MD, Paolo F Caimi, MD, Bingxia Wang, PhD, Chirag Patel, Mi-Sook Kim, Dennis Huszar, Allison J Berger, PhD, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurshim

Blood (2019) 134 (Supplement_1): 1593.

https://doi.org/10.1182/blood-2019-128773

Published: 2019

Journal Articles

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

Jonathon B. Cohen, MDMS, Craig A. Portell, MD, Mehdi Hamadani, MD, Opeyemi Jegede, PhD, Catherine Diefenbach, MD, Kevin A. David, MD, Christopher D. Fletcher, MD, Daniel J. Landsburg, MD, Brad S. Kahl, MD

Blood (2019) 134 (Supplement_1): 1541.

https://doi.org/10.1182/blood-2019-127494

Published: 2019

Journal Articles

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

Amer M. Zeidan, MBBS, MHS, Daniel J. DeAngelo, MD PhD, Jeanne M. Palmer, Christopher S. Seet, MD PhD, Martin S. Tallman, MD, Xin Wei, PhD, Ying Fei Li, PhD, Nanette Hock, RN, MSN, Michael R. Burgess, Kristen Hege, Wendy Stock, MD

Blood (2019) 134 (Supplement_1): 1320.

https://doi.org/10.1182/blood-2019-125363

Published: 2019

Journal Articles

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Constantine S. Tam, MBBS, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Aichun Liu, MD, Anna M. Johnston, Weili Zhao, MD PhD, Fernando Roncolato, BMed, FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Wenyu Li, MD PhD, Ted Shih, PharmD, Xiaoping Zhang, MD MS, Ken Wu, PhD, Yuan Liu, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 1594.

https://doi.org/10.1182/blood-2019-125485

Published: 2019

Journal Articles

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Naval G. Daver, MD, Weiguo Zhang, MD PhD, Richard Graydon, MD PhD, Vikas K Dawra, MBA, PhD, Jingdong Xie, PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1389.

https://doi.org/10.1182/blood-2019-122585

Published: 2019

Journal Articles

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Christine Burnett, Gary Gordon, MD PhD, Thomas Strack, MD, Tara Lehner, MS, PMP, Jack P Higgins, PhD, Jason Tache, DO

Blood (2019) 134 (Supplement_1): 1597.

https://doi.org/10.1182/blood-2019-128503

Published: 2019

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Andrew H. Wei, Jacqueline S Garcia, MD, Uma Borate, MD, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Pierre Peterlin, Joseph G. Jurcic, MD, Guillermo Garcia-Manero, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Jason Harb, PhD, Poonam Tanwani, BSc, Johannes E. Wolff, MD, Meagan Jacoby, MD

Blood (2019) 134 (Supplement_1): 568.

https://doi.org/10.1182/blood-2019-124437

Published: 2019

Journal Articles

Optimizing Hydroxyurea Dosing in Sickle Cell Anemia: The Uganda MTD Study

Chandy C. John, MDMS, Robert Opoka, MMED, Teresa Latham, MA, Heather Hume, MDFRCPC, Maria Nakafeero, Phillip Kasirye, Christopher Ndugwa, Adam Lane, PhD, Russell E. Ware, MD PhD

Blood (2019) 134 (Supplement_1): 520.

https://doi.org/10.1182/blood-2019-125128

Published: 2019

Journal Articles

Effects of Hydroxyurea Treatment on Malaria Infections in Sub-Saharan Africa

Peter Olupot-Olupot, George A. Tomlinson, PhD BSc, MSc, Teresa S. Latham, MA, Patrick T. McGann, MD, Brigida Santos, Banu Aygun, MD, Susan Stuber, MA, Leon Tshilolo, MD PhD, Adam Lane, PhD, Thomas N. Williams, Russell E. Ware, MD PhD

Blood (2019) 134 (Supplement_1): 522.

https://doi.org/10.1182/blood-2019-129251

Published: 2019

Journal Articles

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Haris Ali, MD, David Snyder, MD, Tracy Stiller, MS, Timothy Synold, PhD, Saloomeh Mokhtari, Joycelynne Palmer, PhD, Amandeep Salhotra, MD, Vinod A. Pullarkat, MD, Ji-lian Cai, MD, Stephen J Forman, MD, Matthew Mei, MD, Ryotaro Nakamura, MD

Blood (2019) 134 (Supplement_1): 669.

https://doi.org/10.1182/blood-2019-127445

Published: 2019

Journal Articles

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2019) 134 (Supplement_1): 673.

https://doi.org/10.1182/blood-2019-123854

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

KLF4 Is Needed for Optimal Hydroxyurea Induction of Gamma-Globin in K562 Cells

Pharmacokinetics-Guided Dosing of Hydroxyurea Can Achieve Near-Pancellular Fetal Hemoglobin Expression in Sickle Cell Anemia: F-Cell Analysis As a Benchmark for Disease-Modifying Therapy

Splenomegaly in Children with Sickle Cell Anemia Receiving Hydroxyurea in Sub-Saharan Africa

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Optimizing Hydroxyurea Dosing in Sickle Cell Anemia: The Uganda MTD Study

Effects of Hydroxyurea Treatment on Malaria Infections in Sub-Saharan Africa

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only